What You Should Know:
– Verantos, the leader in high-quality real-world evidence (RWE) forms a strategic partnership with CuriMeta to expand Verantos’ Research Network with de-identified data from 7 million patients,
– The collaboration will enhance the depth and reach of real-world data (RWD) available to life science organizations.
Enhancing RWD Quality and Accessibility
The Verantos Research Network is a unique platform that gathers data from various sources, including academic institutions, community health systems, insurance claims, and disease registries. Their focus on high-quality data ensures researchers have access to the most reliable and comprehensive RWD available.
The two companies will collaborate across various therapeutic areas. CuriMeta’s data will directly support the development and expansion of Verantos’ disease-specific Pragmatic Registries, ultimately leading to more effective treatments and improved patient outcomes.
“The Verantos Evidence Platform uses artificial intelligence (AI) to generate unique disease-specific insights. It is critical that AI models are trained using high-quality patient care data,” said Anand Shroff, President of Verantos. “CuriMeta’s participation will enable us to enhance our disease-specific Pragmatic Registries that are used to accelerate life sciences research.”